ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
This article is part of the Research TopicCancer Epidemiology: Patterns, Causes, and Therapeutic AdvancementsView all 9 articles
Global, regional and national burden of colon and rectum cancer attributable to high fasting plasma glucose: a systematic analysis for the Global Burden of Disease Study 2021
Provisionally accepted- 1Hangzhou Xixi Hospital,Hangzhou Sixth People's Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
- 2Zhejiang Hospital, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Colon and rectum cancer (CRC), as the third most common malignant cancer globally, imposes a substantial public health burden. Emerging evidence highlights hyperglycemia as an independent risk factor for CRC. Estimates of the global burden of high fasting plasma glucose (FPG)-derived CRC are lacking. Methods: We used Global Burden of Disease (GBD) 2021 data to analyze deaths and disability-adjusted life years (DALYs) of CRC attributable to high FPG across 204 countries or territories. GBD standard population was used to calculate age-standardized rates. Joinpoint regression identified temporal trends (1990–2021), while Bayesian age-period-cohort modeling projected future burdens (2022–2036). Health inequalities were assessed by stratifying the analyses according to the sociodemographic index (SDI). Results: Globally, high FPG-related CRC deaths increased from 31,907 (1990) to 82,421 (2021), with DALYs loss rising from 715,716 to 1,750,923. Age-standardized mortality rates (ASMR) and DALY rates (ASDR) increased by an average of 0.31% overall during study period but declined post-2019. High SDI regions bore the highest burden (ASMR: 1.33 per 100,000 persons-year; ASDR: 27.65 per 100,000 persons-year), yet trends stabilized, whereas low-middle SDI regions saw the sharpest rise (ASMR average annual percentage change [AAPC]: 1.82%; ASDR AAPC: 1.77%). Males predominated in the burden of CRC attributable to high FPG than females. Health inequality analysis showed that absolute differences in DALYs slightly increased (slope index of inequality of DALYs increase: 20.251 to 20.292), while relative differences decreased (concentration index of DALYs improvement: -0.344 to -0.294). Projections indicated a 6.1% decline in ASMR and a 1.8% decrease in ASDR by 2036. Conclusion: The escalating burden of high FPG-driven CRC underscores its growing role in CRC epidemiology, particularly in aging populations and regions undergoing rapid urbanization. Persistent gender and socioeconomic disparities necessitate region-tailored interventions, integrating diabetes management with CRC screening and equitable access to novel therapies. These findings advocate for prioritized metabolic risk control in global CRC prevention frameworks to mitigate future burdens.
Keywords: colorectal cancer, DALYs, global burden of disease 2021, healthinequality, High fasting plasma glucose, Mortality
Received: 27 Aug 2025; Accepted: 09 Feb 2026.
Copyright: © 2026 Lu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Gang Xu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
